Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000804244 | SCV000944142 | pathogenic | Hypertrophic cardiomyopathy | 2022-09-19 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg1500 amino acid residue in MYH7. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 15556047, 18660445, 19412328, 24119082). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects MYH7 function (PMID: 19854198, 22155079). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function. ClinVar contains an entry for this variant (Variation ID: 14115). This missense change has been observed in individual(s) with Laing early-onset distal myopathy (PMID: 15322983). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 1500 of the MYH7 protein (p.Arg1500Pro). |
| Revvity Omics, |
RCV003488340 | SCV004236991 | pathogenic | not provided | 2023-04-26 | criteria provided, single submitter | clinical testing | |
| OMIM | RCV000192201 | SCV000035429 | pathogenic | MYH7-related skeletal myopathy | 2004-10-01 | no assertion criteria provided | literature only |